Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Bios
Source: www.businesswire.com
Illumina Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ: PACB) have entered into an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. The suggested acquisition price is equal to a total enterprise value of approximately $1.2 billion on a fully diluted basis. Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems. Illumina is an American based company that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. The acquisition price of $8.00, represents a premium of 71% to PACB’s 30 trading day volume weighted average share price as of the market close on October 31st, 2018
